Evidence map›Paper›PMID 40702277›Full record

ArticleDiscover oncology2025

Mucinous carcinoma of the breast: epidemiological, clinical, and prognostic characteristics; a single-center experience.

Omar Hamdy, Mosab Shetiwy, Mahmoud M Saber, Basma A Eldawody, Shorouq A Kassab, Mariam H Nabih, Mostafa Abdelhakiem, Mona Zaki, Shaimaa M Yussif, Saleh Saleh and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Omar HamdySurgical Oncology Department, Oncology Center, Mansoura University, Mansoura, 35516, Egypt. omarhamdy@mans.edu.eg.ORCID http://orcid.org/0000-0002-2924-4207
Mosab ShetiwySurgical Oncology Department, Oncology Center, Mansoura University, Mansoura, 35516, Egypt.
Mahmoud M SaberFaculty of Medicine, Mansoura University, Mansoura, Egypt.
Basma A EldawodyFaculty of Medicine, Mansoura University, Mansoura, Egypt.
Shorouq A KassabFaculty of Medicine, Mansoura University, Mansoura, Egypt.
Mariam H NabihFaculty of Medicine, Mansoura University, Mansoura, Egypt.
Mostafa AbdelhakiemMedical Oncology Unit, Oncology Center, Mansoura University, Mansoura, Egypt.
Mona ZakiRadiology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Shaimaa M YussifPathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Saleh SalehSurgical Oncology Department, Oncology Center, Mansoura University, Mansoura, 35516, Egypt.
Khaled AbdelwahabSurgical Oncology Department, Oncology Center, Mansoura University, Mansoura, 35516, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMucinous (colloid) carcinoma (MC) of the breast typically affects postmenopausal and elderly women, with a more favorable prognosis compared to invasive breast carcinoma of no special type (IBC-NST). It is characterized by the presence of extracellular mucin and better outcomes. In our work, we presented a fifteen-year yield of a tertiary cancer center for MC.

methodsIn this retrospective study, the data of the patients with MC from January 2009 to August 2023 were retrieved by searching the prospectively registered electronic database of the Oncology Center, Mansoura University. The patients' epidemiological, clinical, pathological, therapeutic, and oncological data were analyzed.

resultsA total of 152 patients with the pathology of MC of the breast were included. The mean age of patients was 55.38 ± 13.82 years. Imaging revealed a unifocal lesion in 93 patients (61.2%). The mean mass size by imaging was 37.25 ± 20.21 mm. Positive lymph nodes (LNs) were detected by imaging in 71 (46.7%) patients. Pathological variants were either pure MC (42.1%) or mixed mucinous ductal carcinoma (57.9%). Luminal A was the most common subtype. Neoadjuvant therapy (NAT) was received by 34.8% of the patients. Mastectomy was done for 103 patients (68.2%). Axillary lymph node dissection was done for 122 patients (80.3%), and sentinel lymph node biopsy (SLNB) was done for 30 patients (19.7%). Adjuvant chemotherapy and radiotherapy were received by 65.1% and 60.8% of patients, respectively, while adjuvant hormonal therapy was received by 84.5%. The mean disease-free survival (DFS) was 43 ± 34.02 months, while the mean overall survival (OAS) was 44.5 ± 33.46 months. Seventeen patients (11.2%) were reported dead during the follow-up period.

conclusionMC of the breast is a unique type of breast cancer. It may mimic benign lesions on imaging. The primary treatment for MC is mostly surgery, followed by adjuvant radiotherapy and systemic therapy. Comparing MC to IBC-NST, the former had a better prognosis and fewer lymphatic metastases, especially with pure MC, which shows a better prognosis.

Indexed as

Breast cancerMucinous carcinomaPrognosisSurvival

Identifiers

PMID40702277
PMCPMC12287483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.